Partnering with GSK

The University of Oxford, a world renowned research institution, and GSK have launched an immuno-prevention programme to advance novel cancer research. This research could then be used to inform future development of vaccines to prevent cancer.

The collaboration will enhance the already established research agreement between Oxford and GSK, which includes the existing five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine.

Muna Therapeutics is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases.

The GSK and Muna research collaboration will leverage Muna’s MiND-MAP platform to identify and validate new therapeutic targets for Alzheimer’s disease, potentially leading to new treatments for patients dealing with significant unmet need.

Relation is a leader in integrating wet lab experimentation, computation, and machine learning to enhance drug discovery.

GSK's collaboration with Relation and their patient-centric discovery platform presents a unique opportunity to accelerate the development of new medicines. Relation will conduct observational studies to create two distinct sets of functional disease data, which will then be analysed using Relation's Lab-in-the-Loop platform.  The collaboration will focus on the identification and validation of new therapeutic targets for fibrotic diseases and osteoarthritis.